Ligand Pharmaceuticals (LGND) Equity Ratio (2010 - 2026)
Ligand Pharmaceuticals recorded quarterly Equity Ratio of 0.65 in Q1 2026, little changed quarter-over-quarter from 0.65 in Q4 2025, and down 25.92% year-over-year from 0.88 in Q1 2025.
Ligand Pharmaceuticals' Equity Ratio history runs 17 years deep, the most recent figure standing at 0.65 for Q1 2026.
- In Q1 2026, Equity Ratio fell 25.92% year-over-year to 0.65; the TTM figure through Mar 2026 stood at 0.65 (down 25.92% YoY), while the FY2025 annual figure was 0.65, down 26.08% from the prior year.
- Equity Ratio came in at 0.65 for Q1 2026 at Ligand Pharmaceuticals, roughly flat from 0.65 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.89 in Q2 2024 to a low of 0.64 in Q3 2025.
- A 5-year average of 0.81 and a median of 0.87 in 2023 frame the typical range for Equity Ratio.
- Across the five-year window, Equity Ratio climbed 24.63% in 2022 and retreated 26.96% in 2025, its largest moves.
- Ligand Pharmaceuticals' Equity Ratio stood at 0.78 in 2022, then gained by 13.65% to 0.89 in 2023, then dropped by 0.96% to 0.88 in 2024, then retreated by 26.08% to 0.65 in 2025, then declined by 0.13% to 0.65 in 2026.
- According to Business Quant data, Equity Ratio over the past three periods registered 0.65, 0.65, and 0.64 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 0.04 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.42 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.73 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.77 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.21 |
| 10 | Ligand Pharmaceuticals | 4.55 Bn | 3.77 Bn | 48.45 Mn | 0.65 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.65 |
| Dec 31, 2025 | 0.65 |
| Sep 30, 2025 | 0.64 |
| Jun 30, 2025 | 0.87 |
| Mar 31, 2025 | 0.88 |
| Dec 31, 2024 | 0.88 |
| Sep 30, 2024 | 0.88 |
| Jun 30, 2024 | 0.89 |
| Mar 31, 2024 | 0.88 |
| Dec 31, 2023 | 0.89 |
| Sep 30, 2023 | 0.87 |
| Jun 30, 2023 | 0.88 |
| Mar 31, 2023 | 0.80 |
| Dec 31, 2022 | 0.78 |
| Sep 30, 2022 | 0.78 |
| Jun 30, 2022 | 0.75 |
| Mar 31, 2022 | 0.72 |
| Dec 31, 2021 | 0.63 |
| Sep 30, 2021 | 0.64 |
| Jun 30, 2021 | 0.63 |
| Mar 31, 2021 | 0.58 |
| Dec 31, 2020 | 0.52 |
| Sep 30, 2020 | 0.56 |
| Jun 30, 2020 | 0.56 |
| Mar 31, 2020 | 0.56 |
| Dec 31, 2019 | 0.51 |
| Sep 30, 2019 | 0.55 |
| Jun 30, 2019 | 0.58 |
| Mar 31, 2019 | 0.56 |
| Dec 31, 2018 | 0.44 |
| Sep 30, 2018 | 0.33 |
| Jun 30, 2018 | 0.33 |
| Mar 31, 2018 | 0.64 |
| Dec 31, 2017 | 0.60 |
| Sep 30, 2017 | 0.61 |
| Jun 30, 2017 | 0.60 |
| Mar 31, 2017 | 0.59 |
| Dec 31, 2016 | 0.57 |
| Jun 30, 2016 | 0.64 |
| Mar 31, 2016 | 0.64 |
| Dec 31, 2015 | 0.47 |
| Sep 30, 2015 | 0.56 |
| Jun 30, 2015 | 0.23 |
| Mar 31, 2015 | 0.13 |
| Dec 31, 2014 | 0.09 |
| Sep 30, 2014 | 0.16 |
| Jun 30, 2014 | 0.64 |
| Mar 31, 2014 | 0.62 |
| Dec 31, 2013 | 0.47 |
| Sep 30, 2013 | 0.44 |
| Jun 30, 2013 | 0.39 |
| Mar 31, 2013 | 0.31 |
| Dec 31, 2012 | 0.25 |
| Sep 30, 2012 | 0.22 |
| Dec 31, 2011 | 0.07 |
| Sep 30, 2011 | 0.02 |
| Jun 30, 2011 | 0.05 |
| Dec 31, 2010 | -0.06 |